Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
56.16
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crispr Therapeutics Ag
< Previous
1
2
...
19
20
21
22
23
24
25
26
Next >
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize
June 01, 2022
One analyst expects multiple new drug launches between 2024-26.
Via
Investor's Business Daily
Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks
May 20, 2022
Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside.
Via
Talk Markets
Analyst Ratings for CRISPR Therapeutics
May 17, 2022
Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
How to Buy Stocks in a Recession
May 16, 2022
The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.
Via
InvestorPlace
5 Cathie Wood Stocks to Buy Now
May 16, 2022
ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider.
Via
InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
May 12, 2022
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
Via
Investor's Business Daily
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
May 10, 2022
Via
Benzinga
$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much
May 02, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About CRISPR Therapeutics
April 28, 2022
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:
Via
Benzinga
3 Cathie Wood Stocks to Count on in Q2
April 26, 2022
These Cathie Wood Stocks have their risks but offer a massive upside potential ahead, especially if you can handle the volatility.
Via
InvestorPlace
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much
April 20, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
April 01, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
3 Best Stocks to Trade Right Now
March 24, 2022
Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative.
Via
InvestorPlace
Fed Rate Hike Rallies Stocks
March 17, 2022
The Federal Reserve led by Jerome Powell hiked interest rates for the first time in three years causing stocks to rally.
Via
Talk Markets
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
March 16, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have...
Via
Benzinga
3 Ark Invest Most-Shorted Stocks to Buy
March 11, 2022
These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers.
Via
InvestorPlace
7 Cathie Wood Stocks That Are Worth Buying in March
March 10, 2022
Many Cathie Wood stocks have suffered losses over the past year, but these companies will likely see strong gains in the coming quarters.
Via
InvestorPlace
3 Cathie Wood Stocks to Buy
March 09, 2022
Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture.
Via
InvestorPlace
Tough Slogging Ahead for Investors, Diversification is Important
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
February 28, 2022
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.
Via
Investor's Business Daily
Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?
February 23, 2022
Savvy investors can generate lucrative returns by investing in companies that look like a number of prime takeover targets.
Via
InvestorPlace
Why Jim Cramer Believes Sirius XM Is Inexpensive
February 23, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ:
Via
Benzinga
What Are Whales Doing With CRISPR Therapeutics
February 22, 2022
A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 15 strange trades.
Via
Benzinga
CRISPR Therapeutics's Return On Capital Employed Insights
February 16, 2022
Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter.
Via
Benzinga
Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal
January 29, 2022
Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up...
Via
Talk Markets
Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years
January 25, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have...
Via
Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
January 14, 2022
A rebound from Monday's lows faded, with the key indexes all down for the week.
Via
Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
< Previous
1
2
...
19
20
21
22
23
24
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.